The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
eli lilly acquires scorpion therapeutics for 2.5 billion in breast cancer push
Eli Lilly has announced a $2.5 billion acquisition of Scorpion Therapeutics’ PI3Kα pipeline, aiming to compete in the breast cancer market against Novartis and Roche. The deal includes the promising candidate STX-478, which has shown a 23% response rate in patients and is designed to selectively target mutant PI3Kα, potentially avoiding adverse effects seen with existing treatments. Lilly will also create a new company for Scorpion's non-PI3Kα assets, retaining Scorpion's staff.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.